Seattle Genetics (SGEN) volatility flattens of FDA recommendation

Seattle Genetics (Nasdaq: SGEN) is recently down 1.2% following the Oncologic Drugs Advisory Committee to the FDA voting 10-0 to recommend that the FDA grant accelerated approval of Adcetris for the treatment of patients with Hodgkin lymphoma who relapse after autologous stem cell transplant. August put option implied volatility is at 53, December is 58; near its six-month average of 56 according to Track Data.

---

Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market - FREE TRIAL!